INmune Bio Inc (INMB)
10.98
-0.20
(-1.75%)
USD |
NASDAQ |
May 17, 16:00
10.98
0.00 (0.00%)
After-Hours: 20:00
INmune Bio Debt to Equity Ratio: 0.2569 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
March 31, 2024 | 0.2569 |
December 31, 2023 | 0.2601 |
September 30, 2023 | 0.2767 |
June 30, 2023 | 0.2926 |
March 31, 2023 | 0.267 |
December 31, 2022 | 0.2445 |
September 30, 2022 | 0.2296 |
Date | Value |
---|---|
June 30, 2022 | 0.2084 |
March 31, 2022 | 0.1919 |
December 31, 2021 | 0.1802 |
September 30, 2021 | 0.1632 |
June 30, 2021 | 0.3319 |
March 31, 2021 | 0.00 |
December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2020
0.3319
Maximum
Jun 2021
0.2074
Average
0.237
Median
Debt to Equity Ratio Benchmarks
Biomarin Pharmaceutical Inc | 0.2144 |
Sarepta Therapeutics Inc | 1.289 |
Dare Bioscience Inc | 0.00 |
Zevra Therapeutics Inc | 0.8808 |
Kodiak Sciences Inc | -- |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 46.83M |
Total Liabilities (Quarterly) | 17.81M |
Shareholders Equity (Quarterly) | 29.02M |
Current Ratio | 1.709 |
Net Debt Paydown Yield | 0.69% |